Anteris Announces Strategic Investment From Medtronic

January 26, 2026—Anteris Technologies Global Corp., a global structural heart company, announced it will conduct three financial transactions that will be used to support the next stage of the company’s clinical strategy.

As summarized in the Anteris press release, the transactions include the following:

• The company is offering to sell $200 million of shares of its common stock through a proposed underwritten public offering. The proposed offer is subject to market and other conditions.
• It intends to grant the underwriters of the public offering a 30-day option to purchase an additional $30 million of shares of common stock from the company at the public offering price, less underwriting discounts and commissions.
• Anteris has agreed to sell to Medtronic (through a wholly owned subsidiary) up to $90.0 million of shares of common stock in a private placement. Completion of the private placement is contingent on completion of the public offering; however, the offering is not contingent on the completion of the private placement.

The company advised that its clinical activities include ongoing recruitment and study execution of the PARADIGM global pivotal trial of the balloon-expandable biomimetic DurAVR transcatheter heart valve in patients with severe aortic stenosis and expansion of manufacturing capabilities. The first European regulatory clearance for the PARADIGM trial was announced in October 2025.

The company further noted that a portion of the proceeds is expected to fund ongoing research and development for v2vmedtech, Inc. The balance will be allocated to working capital and other general corporate purposes determined from time to time.